Aortic stenosis (AS) affects approximately 1.5 million Americans and places a large financial burden on the U.S. healthcare system. Percutaneous catheter delivery of a prosthetic aortic valve, called transcatheter aortic valve replacement (TAVR), has emerged as a treatment option for severe AS. Paravalvular leakage is seen in up to 67% of patients 1-3 years after TAVR implantation, which is in part due to size mismatch of the TAVR device versus the native aortic valve annulus. 3DT is developing a novel 2-in-1 sizing valvuloplasty conductance balloon (SVCB) catheter system that serves as a standard valvuloplasty balloon for aortic valve dilatation prior to implant (all TAVR procedures involve valvuloplasty) as well as a valuable tool that accurately measures and displays real-time aortic annulus size during inflation.